Aquestive Therapeutics (NASDAQ:AQST) CEO Daniel Barber Sells 8,257 Shares

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 8,257 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $4.29, for a total value of $35,422.53. Following the completion of the sale, the chief executive officer directly owned 660,574 shares of the company’s stock, valued at approximately $2,833,862.46. This trade represents a 1.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Barber also recently made the following trade(s):

• On Tuesday, March 10th, Daniel Barber sold 180,677 shares of Aquestive Therapeutics stock. The shares were sold at an average price of $4.17, for a total value of $753,423.09.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $4.14 on Tuesday. The stock has a market cap of $519.36 million, a PE ratio of -6.79 and a beta of 1.50. The stock has a 50-day moving average of $4.16 and a 200-day moving average of $4.74. Aquestive Therapeutics, Inc. has a one year low of $2.22 and a one year high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. The company had revenue of $14.45 million during the quarter, compared to the consensus estimate of $10.90 million. As a group, research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Institutional Trading of Aquestive Therapeutics

A number of large investors have recently bought and sold shares of the business. Arete Wealth Advisors LLC bought a new stake in Aquestive Therapeutics during the 1st quarter worth approximately $504,000. ADAR1 Capital Management LLC increased its stake in Aquestive Therapeutics by 103.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after purchasing an additional 264,000 shares in the last quarter. Royal Bank of Canada increased its stake in Aquestive Therapeutics by 133.0% during the 1st quarter. Royal Bank of Canada now owns 28,951 shares of the company’s stock worth $120,000 after purchasing an additional 16,525 shares in the last quarter. Quantinno Capital Management LP increased its stake in Aquestive Therapeutics by 52.8% during the 1st quarter. Quantinno Capital Management LP now owns 18,014 shares of the company’s stock worth $75,000 after purchasing an additional 6,221 shares in the last quarter. Finally, Corsair Capital Management L.P. boosted its position in Aquestive Therapeutics by 16.7% during the 1st quarter. Corsair Capital Management L.P. now owns 70,000 shares of the company’s stock worth $290,000 after acquiring an additional 10,000 shares during the last quarter. 32.45% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on AQST shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Monday, April 20th. Lake Street Capital set a $6.00 target price on Aquestive Therapeutics in a research note on Tuesday, February 3rd. Oppenheimer initiated coverage on Aquestive Therapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $8.00 target price for the company. Finally, Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $8.80.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.